GV.PA Genomic Vision SA (EURONEXT) €0.0018 pre-market 09 Jan 2026: volume spike
GV.PA stock opens pre-market at €0.0018 on EURONEXT on 09 Jan 2026, trading well above its 1-day low with a heavy volume surge. The move follows sustained low prices and very high intraday liquidity: today’s volume is 38,489,238 versus an average 14,217,513, a relative volume of 2.71. For most-active traders, the immediate question is whether this volume reflects short-term speculation, news flow or technical buying around the low price.
Pre-market price and volume snapshot for GV.PA stock
GV.PA stock is quoted at €0.0018, up 5.88% from the previous close of €0.0017. Today’s intraday range is €0.0015–€0.0020, while the 52-week range is €0.0014–€0.0940. Volume is elevated at 38,489,238 shares versus an average of 14,217,513, signalling unusually active trading in the pre-market session.
Fundamentals and valuation for GV.PA stock
Genomic Vision SA shows distressed fundamentals: EPS is -0.11 and the reported PE is negative (-0.02). Market capitalisation stands at €693,191, and enterprise value is €2,369,191. Price-to-sales is 0.47 and price-to-book is negative (-0.19), reflecting cumulative losses and negative equity per share. Current ratio is 0.91, while cash per share is €0.00557, indicating limited short-term liquidity.
Technical and trading context for GV.PA stock
Technically, GV.PA stock trades well below its moving averages: the 50-day average is €0.004844 and the 200-day average is €0.013997, showing a prolonged downtrend. Short-term volatility is high: day low €0.0015 and high €0.0020. The stock’s low absolute price amplifies percentage moves and creates execution and liquidity risk for larger orders.
Meyka AI rates GV.PA with a score out of 100 and forecast for GV.PA stock
Meyka AI rates GV.PA with a score out of 100 as 61.95 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects a 12-month base target of €0.006 versus the current €0.0018, implying an upside of 233.33%. Forecasts are model-based projections and not guarantees; they assume no major dilution and modest operational recovery.
Catalysts, risks and sector context for GV.PA stock
Genomic Vision operates in Medical – Diagnostics & Research and lists strategic alliances and R&D ties with established players. Sector peers trade materially richer: Healthcare average P/E is 36.02, underlining valuation gaps. Principal risks are continued negative earnings (net margin and ROE are negative), potential equity dilution given 385,105,984 shares outstanding, and limited cash runway given negative operating cash flow per share (-0.0323).
Most-active trading strategy and position guidance for GV.PA stock
For most-active traders, GV.PA stock is a high-risk, high-volatility trade suitable only for small position sizes and tight risk controls. Limit orders are preferable to market orders given thin bid sizes. Consider a cautious sizing rule (no more than 0.5%–1.0% of a diversified portfolio) and predefined stop-losses given potential rapid downside to recent lows near €0.0014.
Final Thoughts
Key takeaways: GV.PA stock is trading at €0.0018 pre-market on EURONEXT with a clear volume surge that makes it one of the most active small-cap names this session. Fundamentals remain weak—EPS -0.11, negative equity per share and constrained liquidity—so any rebound must be validated by improved cash flow or credible funding. Meyka AI’s model projects a 12-month base target of €0.006, an implied upside of 233.33% compared with the current €0.0018, but this depends on execution, no further dilution, and sector stability. Traders focused on most-active screens should treat GV.PA as speculative: use tight sizing, strict stops and track corporate updates closely. For a deeper data read, view company filings and the latest coverage; Meyka AI provides the underlying data as an AI-powered market analysis platform to help frame risk and opportunity. Forecasts are model-based projections and not guarantees.
FAQs
What is driving the pre-market activity in GV.PA stock?
Pre-market activity in GV.PA stock is driven by heavy volume (38,489,238 today), low absolute price and short-term traders seeking volatility. No confirmed company-specific news was published; monitor corporate releases and sector announcements for catalysts.
How does Meyka AI grade GV.PA stock and what does it mean?
Meyka AI rates GV.PA with a score of 61.95 (Grade B | HOLD). The grade blends benchmark, sector comparison, metrics and forecasts. It signals cautious interest but not a clear buy recommendation.
What are the realistic price targets for GV.PA stock?
Meyka AI’s base 12-month target is €0.006; a conservative bear case could be €0.001, and a bull recovery scenario could reach €0.015. These are model projections, not guarantees.
Should investors include GV.PA stock in a diversified portfolio?
GV.PA stock is speculative and may be included in a very small allocation for risk-tolerant investors. Use strict position sizing and consider liquidity and dilution risks before adding exposure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
